Dr. Walker joins to lead Scenic’s transition into clinical development and shape its clinical strategy Lead program SC6177 is advancing toward the clinic with a first-in-class approach to restoring lysosomal function, a key driver of multiple neurodegenerative disease Amsterdam, The Netherlands — 10 September 2026: Scenic Biotech (“Scenic” or “the Company”), a neurometabolic company whose […]